Patient Resources

PICASSO: Phase 3 Randomized Control Trial now enrolling in Soft-Tissue Sarcoma

ZIOPHARM Oncology is now enrolling patients in a Phase III randomized controlled trial (RCT) of palifosfamide combined with doxorubicin for the treatment of patients with unresectable or metastatic soft-tissue sarcoma (STS): A Phase III multicenter, parallel group, randomized study of palIfosfamide tris plus doxorubiCin versus doxorubicin in subjects with unresectAble or metastatic Soft-tissue SarcOma (PICASSO). 

Eligible patients have been diagnosed with advanced, histologically confirmed STS excluding alveolar soft-part sarcoma, chondrosarcoma, dermatofibrosarcoma, Ewing sarcoma, GIST, Kaposi sarcoma, mixed mesodermal tumor, osteosarcoma, radiation induced sarcoma and unresectable low-grade liposarcoma and have front line or second line metastatic disease or advanced local disease.  Patients may have failed adjuvant therapy.  Additional information regarding the PICASSO trial for both patients and providers can be found at http://www.picasso3trial.com or http://www.clinicaltrial.gov. A listing of participating study sites can also be found at this website.

Programs & Resources

Patient Resources

Information on sarcoma subtypes, treatments, clinical trials, and other important resources for sarcoma patients and families.

Sarcoma Patient Registry

Information on the Sarcoma Patient Registry. If you are diagnosed with sarcoma, please consider joining the Registry.

Research Grants

Information on applying for a sarcoma research grant, current research funded by the SFA, and past research grants.